Liver-specific inactivation of Cideb improves metabolic profiles and ameliorates steatohepatitis and fibrosis in animal models for MASH

Liver-specific inactivation of Cideb improves metabolic profiles and ameliorates steatohepatitis and fibrosis in animal models for MASH

Germline mutations of CIDEB, a lipid droplets (LDs)-associated protein, confer protection against various liver diseases in humans. It remains to be determined whether liver-specific inhibition of CIDEB will bring clinical benefits. We aim to establish pharmacological proof of concept by testing Gal...

Full description

Saved in:
Bibliographic Details
Main Authors: Jianhua Zhang, Xujie Liu, Xian Jin, Xudong Mao, Xueli Xu, Xing Zhang, Ke Shang, Yuan Xu, Yanhuan Zhang, Guofeng Meng, Ming Yue, Guoqing Cai, Song Yang, Jinyu Huang, Jianwu Fang, Ling Pan, Lei Jiang, Stella Shi, Jianyong Shou
Format: Article
Language:English
Published: Elsevier 2025-04-01
Series:Pharmacological Research
Subjects:
MASLD
GalNAc
Drug discovery
NASH
NAFLD
HSD17B13
Online Access:http://www.sciencedirect.com/science/article/pii/S1043661825000891
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S1043661825000891

Similar Items